abstract |
The present disclosure is directed to methods for reducing the neuronal damage associated with cerebrovascular disease, such as stroke or cerebral edema, by administering R(−)-desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. The cerebrovascular disease may be caused by ischemia or hypoxia. |